ArticleLiver cancer2023
Surveillance, Diagnosis, and Treatment Outcome of Hepatocellular Carcinoma in Japan: 2023 Update.
Article in Liver cancer, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed.
- Hepatocellular carcinoma surveillance in Europe: challenges and lessons from global practice.The Lancet regional health. Europe · 2026Review
- Nivolumab plus Ipilimumab versus Lenvatinib or Sorafenib as First-Line Treatment for Unresectable Hepatocellular Carcinoma: CheckMate 9DW Japanese Subgroup Analysis.Liver cancer · 2026Article
- PERSoN4: A multiparametric ultrasound model to improve CEUS LI-RADS for HCC.JHEP reports : innovation in hepatology · 2026Article
- Comparison of patients with HCC with and without MASLD after surgical resection.JHEP reports : innovation in hepatology · 2026Article
- Hepatocellular Carcinoma in the Eastern World: Screening, Diagnosis, Staging and Treatment.Current pharmaceutical design · 2026Review
- Putative Role of Fatty Acid Metabolic Therapy Using Ketogenic Diet and HIF-1α Inhibition in Hepatocellular Carcinoma: Evidence from an In Vitro Study.International journal of molecular sciences · 2025Article
- Lancet Commission 2025 Calls for Urgent Global Action: 60% of Liver Cancers Are Preventable.Liver cancer · 2025Article
- Performance of the multi-target hepatocellular carcinoma blood test: Design and rationale of the ALTUS study.Hepatology communications · 2025Article
- First-Line Lenvatinib plus Pembrolizumab for Hepatocellular Carcinoma: Post hoc Analysis of Japanese Patients from the Phase 3 LEAP-002 Trial.Liver cancer · 2025Article
- Opportunities to improve surveillance of hepatocellular carcinoma in Australia.The Medical journal of Australia · 2025Article
- Article
- Systemic Therapy Combined with Locoregional Therapy in Intermediate-stage Hepatocellular Carcinoma.Interventional radiology (Higashimatsuyama-shi (Japan) · 2025Review
- Validation of an albumin-indocyanine green-based China liver cancer staging system to evaluating resectable hepatocellular carcinoma patients and comparison with the Child-Pugh-based China liver cancer staging system.Frontiers in oncology · 2025Article
- Combination Assay of MethylatedLiver cancer · 2024Article
- Urgent Global Need for PIVKA-II and AFP-L3 Measurements for Surveillance and Management of Hepatocellular Carcinoma.Liver cancer · 2024Article
- Adjuvant and neoadjuvant immunotherapies in hepatocellular carcinoma.Nature reviews. Clinical oncology · 2024Review
- Current Therapeutic Strategies for Hepatocellular Carcinoma in Japan.Liver cancer · 2023Article
- All Stages of Hepatocellular Carcinoma Patients Benefit from Systemic Therapy Combined with Locoregional Therapy.Liver cancer · 2023Article
- Drug-Off Criteria in Patients with Hepatocellular Carcinoma Who Achieved Clinical Complete Response after Combination Immunotherapy Combined with Locoregional Therapy.Liver cancer · 2023Article
- Redefining HCC Surveillance in India: A Call for Innovative and Inclusive Strategies.Journal of clinical and experimental hepatologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.